Cargando…
Immunohistochemical analysis in ethinylestradiol-treated breast cancers after prior long-term estrogen-deprivation therapy
BACKGROUND: Estrogen receptor (ER) positive breast cancer can often be treated by hormone therapy; however a certain population of ER-positive patients become resistant to hormone therapy after long-term hormone treatment. Ethinylestradiol (EE2) is a derivative of estrogen, which has shown promising...
Autores principales: | Omoto, Yoko, Takeshita, Takashi, Yamamoto, Yutaka, Yamamoto-Ibusuki, Mutsuko, Hayashi, Mitsuhiro, Sueta, Aiko, Fujiwara, Saori, Taguchi, Tetsuya, Iwase, Hirotaka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353819/ https://www.ncbi.nlm.nih.gov/pubmed/25774336 http://dx.doi.org/10.1186/s40064-015-0851-8 |
Ejemplares similares
-
Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients
por: Takeshita, Takashi, et al.
Publicado: (2016) -
Prognostic role of PIK3CA mutations of cell‐free DNA in early‐stage triple negative breast cancer
por: Takeshita, Takashi, et al.
Publicado: (2015) -
Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients
por: Takeshita, Takashi, et al.
Publicado: (2017) -
Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients
por: Takeshita, Takashi, et al.
Publicado: (2017) -
Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients
por: Takeshita, Takashi, et al.
Publicado: (2017)